Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John H Rex

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 19, 2011
Ocular manifestations of candidemiaAstrid M L Oude Lashof, Aniki Rothova, Jack D Sobel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 5, 2005
Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humansLuis Ostrosky-Zeichner, Barbara D Alexander, Daniel H Kett, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2026
Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy studyJohan Maertens, Sharon C A Chen, George R Thompson, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 31, 2025
Paradoxical worsening on olorofim in patients undergoing treatment for invasive fungal diseasesGeorge R Thompson, Anke H W Bruns, Jannik Helweg-Larsen, et al.
Nature Reviews. Drug Discovery|July 30, 2016
Accelerating global innovation to address antibacterial resistance: introducing CARB-XKevin Outterson, John H Rex, Tim Jinks, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2003
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United StatesLuis Ostrosky-Zeichner, John H Rex, Peter G Pappas, et al.
Antimicrobial Agents and Chemotherapy|September 24, 2008
Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard methodLuis Ostrosky-Zeichner, John H Rex, Michael A Pfaller, et al.
The Lancet. Infectious Diseases|October 20, 2018
Analysis of the clinical antibacterial and antituberculosis pipelineUrsula Theuretzbacher, Simon Gottwalt, Peter Beyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2003
A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patientsPeter G Pappas, John H Rex, Jeannette Lee, et al.
Nature Reviews. Microbiology|October 19, 2018
Developmental roadmap for antimicrobial susceptibility testing systemsAlex van Belkum, Till T Bachmann, Gerd Lüdke, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 19, 2011
Ocular manifestations of candidemiaAstrid M L Oude Lashof, Aniki Rothova, Jack D Sobel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 5, 2005
Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humansLuis Ostrosky-Zeichner, Barbara D Alexander, Daniel H Kett, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2026
Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy studyJohan Maertens, Sharon C A Chen, George R Thompson, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 31, 2025
Paradoxical worsening on olorofim in patients undergoing treatment for invasive fungal diseasesGeorge R Thompson, Anke H W Bruns, Jannik Helweg-Larsen, et al.
Nature Reviews. Drug Discovery|July 30, 2016
Accelerating global innovation to address antibacterial resistance: introducing CARB-XKevin Outterson, John H Rex, Tim Jinks, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2003
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United StatesLuis Ostrosky-Zeichner, John H Rex, Peter G Pappas, et al.
Antimicrobial Agents and Chemotherapy|September 24, 2008
Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard methodLuis Ostrosky-Zeichner, John H Rex, Michael A Pfaller, et al.
The Lancet. Infectious Diseases|October 20, 2018
Analysis of the clinical antibacterial and antituberculosis pipelineUrsula Theuretzbacher, Simon Gottwalt, Peter Beyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2003
A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patientsPeter G Pappas, John H Rex, Jeannette Lee, et al.
Nature Reviews. Microbiology|October 19, 2018
Developmental roadmap for antimicrobial susceptibility testing systemsAlex van Belkum, Till T Bachmann, Gerd Lüdke, et al.
Pageof 10